2nd Annual Genomics Meeting: Genomics and Translational Medicine in Myeloma

July 12 - 13, 2024 - Hilton Barcelona, Barcelona, Spain

The IMS Genomics Meeting was developed in response to the IMS-FDA joint workshop to further consider essential needs in myeloma. The initial invitation-only meeting in 2023 provided an opportunity for myeloma experts from around the world to develop a consensus to define ‘high-risk multiple myeloma’. The publication with the results and recommendations from this meeting has been submitted for review. Building upon this success, the Second IMS Genomics Meeting will be a public meeting led by global myeloma KOL.

In addition to which, this day and a half-long meeting will include sessions on:

  • Risk Stratification validation
  • Genomically targeted therapies
  • New technologies
  • Genomic Biomarkers for stratification of clinical studies
  • New clinical trials for patients with HR disease
Our sponsors:
Silver

Tentative Agenda 

Register Today

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Login
See All of the Member Benefits
Become a Member Today

Stay updated on our Events